Cyteir nets $40M for rad syn­thet­ic lethal­i­ty plat­form — throw­ing an­oth­er mon­key wrench at cell re­pair

A cell is like a speed­boat, says Cyteir Ther­a­peu­tics founder Markus Ren­schler. When all parts are sound — the hull for­ti­fied, the en­gine steady — it’s smooth sail­ing. But you could go faster. You could drill a hole in the front, and sure you’d be in greater dan­ger but you’d be glid­ing. At that point, though, a hole in the back would be dead­ly.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.